TLX.AX Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 09:10):

Stats
Dzisiejszy wolumen	1.18M
Średni wolumen	1.22M
Kapitalizacja rynkowa	5.04B
EPS	$0 ( 2024-02-21 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	762.00
ATR14	$0.0120 (0.08%)

Wolumen Korelacja

Długi: 0.03 (neutral)

Krótki: 0.02 (neutral)

Signal:(65.52) Neutral

Telix Pharmaceuticals Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Telix Pharmaceuticals Korelacja - Waluta/Towar

-0.28
( neutral )

-0.22
( neutral )

0.00
( neutral )

-0.16
( neutral )

0.53
( weak )

Telix Pharmaceuticals Finanse

Annual	2023
Przychody:	$496.66M
Zysk brutto:	$308.50M (62.12 %)
EPS:	$0.0163

FY	2023
Przychody:	$496.66M
Zysk brutto:	$308.50M (62.12 %)
EPS:	$0.0163

FY	2022
Przychody:	$160.10M
Zysk brutto:	$29.34M (18.32 %)
EPS:	$-0.340

FY	2021
Przychody:	$4.90M
Zysk brutto:	$2.35M (47.98 %)
EPS:	$-0.313

Financial Reports:

No articles found.

Telix Pharmaceuticals

Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.